CompletedNot Applicable

Oncologic Impact of Pancreatic Fistula

France382 participantsStarted 2009-01-30

Plain-language summary

Clinically-relevant post-operative fistula is a major complication after DP, but it did not affect post-operative therapeutic path nor oncologic long-term outcomes. CR-POPF was not a predictive factor for disease recurrence and it was not associated with an increased incidence of peritoneal or local relapse.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: \- patient with resectable pancreatic ductal adenocarcinoma (PDAC) of the body and the tail of the pancreas undergone surgery Exclusion criteria: * metastatic diseases (including para-aortic lymph nodes involvement) * PDAC arising from Intraductal Papillary Mucinous Neoplasms (IPMN) * resection for premalignant lesions including high-grade Pancreatic Intraepithelial Neoplasia (PanIN) or adenocarcinoma in situ (Tis) * histological diagnosis other than PDAC * all R2 resections.

What they're measuring

impact of clinically relevant (CR-) POPF

Timeframe: 10 years

Trial details

NCT IDNCT04348084

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-01

View on ClinicalTrials.gov More PDAC of the Body and the Tail of the Pancreas trials